Eli Lilly’s and Novo Nordisk’s results were mainly driven by growth in GLP-1 weight-loss and diabetes drugs, while Pfizer and Merck raised guidance due to strength outside of COVID and key oncology and new drugs, despite some companies revising earnings forecasts due to acquisitions and operational initiatives.